SJÖGREN'S SYNDROME
Clinical trials for SJÖGREN'S SYNDROME explained in plain language.
Never miss a new study
Get alerted when new SJÖGREN'S SYNDROME trials appear
Sign up with your email to follow new studies for SJÖGREN'S SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for Sjögren's syndrome in Long-Term safety trial
Disease control Recruiting nowThis study looks at the long-term safety of a drug called dazodalibep for people with Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. About 844 people who completed a prior phase 3 study will receive the drug for up to 48 more weeks. The main goal is to …
Matched conditions: SJÖGREN'S SYNDROME
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Engineered immune cells aim to tame childhood arthritis and lupus
Disease control Recruiting nowThis early-phase trial is testing a new treatment called KN5601, which uses a patient's own immune cells (NK cells) that have been engineered to target and destroy harmful B cells. The goal is to see if it is safe and can help children aged 5 and older with rheumatic diseases lik…
Matched conditions: SJÖGREN'S SYNDROME
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Desperate patients get early access to experimental drug ianalumab
Disease control AVAILABLEThis program provides early access to the drug ianalumab (VAY736) for patients with serious or life-threatening conditions like immune thrombocytopenia or Sjögren's syndrome who have no other treatment options. It is not a clinical trial but a managed access program where doctors…
Matched conditions: SJÖGREN'S SYNDROME
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Experimental CAR t therapy takes on autoimmune diseases
Disease control Recruiting nowThis early-stage trial tests a new treatment called AFN50 for people with autoimmune diseases that haven't responded to standard therapies. AFN50 is a type of CAR T-cell therapy designed to target and destroy faulty immune cells. The study will enroll 18 adults to check if the tr…
Matched conditions: SJÖGREN'S SYNDROME
Phase: EARLY_PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cell therapy hopes to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…
Matched conditions: SJÖGREN'S SYNDROME
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Immune reset: CAR-T therapy targets lupus, MS, and more
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…
Matched conditions: SJÖGREN'S SYNDROME
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered immune cells take on autoimmune diseases in early trial
Disease control Recruiting nowThis early-phase study is testing a new cell therapy called LUCAR-DKS1 in 36 adults with relapsed or refractory autoimmune diseases like lupus. Participants receive their own modified NK cells after a short chemotherapy prep. The main goals are to check safety, find the right dos…
Matched conditions: SJÖGREN'S SYNDROME
Phase: EARLY_PHASE1 • Sponsor: Nanjing Legend Biotech Co. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New eye drops aim to soothe Sjögren's dry eye
Symptom relief Recruiting nowThis study tests whether a protein-based eye drop (rhPRG4) can safely relieve dry eye symptoms in people with Sjögren's syndrome. About 80 adults will receive either the active drops or a placebo for 28 days. The main goal is to see if the drops can clear corneal staining, a sign…
Matched conditions: SJÖGREN'S SYNDROME
Phase: PHASE2 • Sponsor: Lubris Bio Pty Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC